Non-Hodgkin's Lymphoma
399
22
35
247
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
121 trials with published results (30%)
Research Maturity
247 completed trials (62% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
18.0%
72 terminated out of 399 trials
77.4%
-9.1% vs benchmark
10%
40 trials in Phase 3/4
49%
121 of 247 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 247 completed trials
Clinical Trials (399)
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Biology Studies of Hematologic Cancers
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
Expanded Access to Venetoclax
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies